Relmada Therapeutics said Wednesday morning that a Phase 3 study testing its major depression drug, REL-1017, is likely to fail, cratering its stock price. …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Major changes aimed at treating psychiatric patients in the community instead of hospital requires clear and strong leadership, as well as and long-term political and
Shash Anand, SVP, Product Strategy, SOTI Data is central to a wide range of exciting innovations in healthcare. Wearable devices that monitor vital signs in
Share this article CPI’s Oligonucleotide Manufacturing Innovation Centre of Excellence in Scotland could create a global hub. Credit: CPI. Oligonucleotides have long been heralded as